Search results from popular keywords

2008 was characterized by high sales growth. Sales were diversified, both geographically and at industry level, and Novozymes continued to increase its market presence. Total sales for the y...

In 2008 Novozymes’ stock price performed better than most benchmark indexes. The stock price was, however, subject to high volatility throughout the year. Novozymes’ stock price developed be...

Market and customers Novozymes sells its products worldwide and is subject to the financial and political risks that this naturally entails. Growth in individual markets is therefore influen...

The consolidated financial statements of the Novozymes Group have been prepared in accordance with the International Financial Reporting Standards (IFRS), as adopted in the EU, and additiona...

Group Companies Issued common stock Percentage paid-up of shares Country Activity stock owned Novozymes Australia Pty. Ltd. Australia AUD 500,000 100 Novozymes Biopharma Holdings AU Ltd. Aus...

The Board of Directors and Executive Management have considered and approved the Annual Report for 2008 of Novozymes A/S. The consolidated financial statements are presented in accordance wi...

To the Shareholders of Novozymes A/S We have audited the Annual Report of Novozymes A/S for 2008, which comprises the Statement of the Board of Directors and Executive Management, Management...

Subject matter, responsibilities, objectives and scope of assurance report The environmental and social data and information presented in the Annual Report on which this Assurance Report is ...

Novozymes supports The Global Reporting Initiative's framework for sustainability reporting. Accordingly, GRI reporting has been an integrated part of Novozymes' reporting platform since 200...

Statement of continued support At Novozymes, sustainability is a fundamental part of the way we make decisions, set our priorities, and conduct our business. We believe that long-term busine...